Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cyclo Therapeutics (CYTH)
NASDAQ:CYTH
Cyclo Therapeutics (CYTH) Stock Price & Analysis
188 Followers
CYTH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.89 - $2.12
Previous Close$1.2
Volume3.93K
Average Volume (3M)34.47K
Market Cap
$34.91M
Enterprise Value$26.12M
Total Cash (Recent Filing)$9.25M
Total Debt (Recent Filing)$1.03M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Aug 13, 2024EPS Estimate
-$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding28,615,740
10 Day Avg. Volume18,323
30 Day Avg. Volume34,465
Standard Deviation0.23
R-Squared0.00445
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)7.82
Price to Sales (P/S)34.56
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue24.27
Enterprise Value/Gross Profit26.33
Enterprise Value/Ebitda-1.69
Forecast
1Y Price Target
$2.80Price Target Upside129.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Cyclo Therapeutics News
PremiumPre-Earnings
Is CYTH a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Clinical TrialsCompletion of enrollment and dosing of 94 patients in Phase 3 pivotal study for Trappsol Cyclo in Niemann-Pick Disease Type C.
Market OpportunitiesNPC and Alzheimer's Disease present large market opportunities for Cyclo Therapeutics' cyclodextrin-based therapies.
Regulatory ProgressPlans to submit marketing applications with the FDA and EMA pending significant data from the 48-week interim analysis.
Bears Say
Cash ReservesThe company has only 5-6 months of cash runway, posing a risk to its financial stability.
EarningsThe company reported revenues of $0.2M, which significantly missed the consensus estimate of $0.4M.
Financial PerformanceA net loss of $0.15 per diluted share was reported, falling short of the expected net loss of $0.19 per diluted share.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
CYTH FAQ
What was Cyclo Therapeutics’s price range in the past 12 months?
Cyclo Therapeutics lowest stock price was $0.89 and its highest was $2.12 in the past 12 months.
What is Cyclo Therapeutics’s market cap?
Currently, no data Available
When is Cyclo Therapeutics’s upcoming earnings report date?
Cyclo Therapeutics’s upcoming earnings report date is Aug 13, 2024 which is in 41 days.
How were Cyclo Therapeutics’s earnings last quarter?
Cyclo Therapeutics released its earnings results on May 16, 2024. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.193 by $0.043.
Is Cyclo Therapeutics overvalued?
According to Wall Street analysts Cyclo Therapeutics’s price is currently Undervalued.
Does Cyclo Therapeutics pay dividends?
Cyclo Therapeutics does not currently pay dividends.
What is Cyclo Therapeutics’s EPS estimate?
Cyclo Therapeutics’s EPS estimate is -$0.16.
How many shares outstanding does Cyclo Therapeutics have?
Cyclo Therapeutics has 28,614,384 shares outstanding.
What happened to Cyclo Therapeutics’s price movement after its last earnings report?
Cyclo Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.193. Following the earnings report the stock price went down -4.196%.
Which hedge fund is a major shareholder of Cyclo Therapeutics?
Currently, no hedge funds are holding shares in CYTH
---
Cyclo Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.80 (129.51% Upside)
$2.80 (129.51% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.52%
12-Months-Change
Fundamentals
Return on Equity
-9999.00%
Trailing 12-Months
Asset Growth
74.85%
Trailing 12-Months
Company Description
Cyclo Therapeutics
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product candidates include Trappsol Cyclo, which treats Neimann-Pick Type C disease. The firm focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.
---
CYTH Stock 12 Month Forecast
Average Price Target
$2.80
▲(129.51% Upside)
Technical Analysis
Best Analysts Covering CYTH
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-28.80%
reiterated a buy rating 4 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -28.80% per trade.
---